Michel Vounatsos
About Michel Vounatsos
Michel Vounatsos (age 63) is an independent director of Revvity (RVTY) since 2020. He is Chair of the Nominating & Corporate Governance Committee and a member of the Audit Committee; the board has determined he is an “audit committee financial expert.” He previously served as CEO of Biogen (2017–2022) and Biogen’s EVP & Chief Commercial Officer (2016–2017), following a 20-year career at Merck in senior roles across the U.S., Europe, and China; he holds a medical certificate from Université Victor Segalen Bordeaux II and an MBA from HEC Paris .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Biogen Inc. | Chief Executive Officer; Director | 2017–2022 | Led a Fortune 500 biotech; brings leadership and industry expertise to Revvity |
| Biogen Inc. | EVP, Chief Commercial Officer | 2016–2017 | Drove commercial strategy and transformation |
| Merck & Co., Inc. | President, Primary Care & Customer Centricity (U.S.); various leadership roles | ~20 years (prior to 2016) | Transformed go-to-market model; expanded mature and emerging markets; roles across Europe and China |
| Ciba-Geigy | Management positions | Prior to Merck | Early career pharma management experience |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Zai Lab Ltd. (public) | Director | Current | Public company board experience; potential industry interlock (no related transactions disclosed by Revvity) |
| Liryc – Electrophysiology & Heart Modeling Institute (Univ. Bordeaux) | Supervisory Board member | Current | Scientific oversight role |
Board Governance
- Independence: Board determined Vounatsos is independent under NYSE rules; also meets additional independence for audit committees under Rule 10A-3 .
- Committee assignments:
- Audit Committee member; designated “audit committee financial expert”; audit met 8 times in FY2024 .
- Nominating & Corporate Governance Committee Chair; committee met 3 times in FY2024 .
- Board meetings: Board met 6 times in FY2024; each director attended ≥75% of board and committee meetings; all directors attended the annual meeting (virtual) .
- Board structure: Independent Chair; 9 of 10 directors independent; non-classified board; majority vote standard in uncontested director elections; independent directors meet without management .
| Governance Item | Detail |
|---|---|
| Director since | 2020 |
| Independence | Independent |
| Audit Committee | Member; financial expert; 8 meetings in FY2024 |
| Nominating & Corporate Governance | Chair; 3 meetings in FY2024 |
| Board meetings FY2024 | 6 |
| Attendance FY2024 | ≥75% for each director; annual meeting attended |
Fixed Compensation
| Component (2024 Board Year) | Amount/Detail | Vesting/Notes |
|---|---|---|
| Cash retainer | $90,000 annual (paid quarterly) | Prorated for partial year or <75% attendance |
| Committee Chair retainer | $15,000 for Nominating & Corporate Governance Chair | Applies for committee chairs |
| Audit/Comp Chair retainers | $25,000 (Audit Chair), $20,000 (Comp & Benefits Chair) | Not applicable to Vounatsos (not chair of Audit/Comp) |
| 2024 fees earned (Vounatsos) | $105,000 cash | Composition: $90k base + $15k chair |
| Equity – common shares | 1,218 shares; grant-date fair value $124,967; granted May 1, 2024; not subject to vesting | Fully unrestricted at grant |
| Equity – RSUs | 977 RSUs; grant-date fair value $99,967; granted May 1, 2024 | 100% vests at next annual meeting, or earlier upon death, disability, qualifying retirement, or termination within 12 months post change-in-control |
| Total 2024 compensation (Vounatsos) | $329,933 (cash $105,000 + stock awards $224,933) | — |
Performance Compensation
Directors do not receive performance-based equity; non-employee director equity consists of time-based RSUs and unrestricted share grants. No options outstanding for non-employee directors as of Dec 29, 2024 .
| Incentive Component | Metric | Quantum | Grant Date | Vesting | Change-in-Control Terms |
|---|---|---|---|---|---|
| RSUs (Vounatsos) | None (time-based) | 977 RSUs; $99,967 grant-date fair value | May 1, 2024 | 100% at next annual meeting; or earlier upon death/disability/qualifying retirement; or termination within 12 months post change-in-control | Accelerates upon termination within 12 months after change-in-control |
| Shares (Vounatsos) | None (unrestricted) | 1,218 shares; $124,967 grant-date fair value | May 1, 2024 | No vesting/restrictions | N/A |
Other Directorships & Interlocks
| Company | Relationship to Revvity | Notes |
|---|---|---|
| Zai Lab Ltd. | Potential industry interlock (biotech) | No related party transactions disclosed by Revvity; related party transactions are overseen under a formal board policy |
Expertise & Qualifications
- CEO experience at a public company; strategic and operational leadership in biotech and pharma .
- Audit committee financial expertise; financial literacy affirmed by board .
- International commercial leadership across U.S., Europe, China; transformation and go-to-market expertise .
- Academic credentials in medicine and business (HEC Paris MBA) .
Equity Ownership
| Item | Detail |
|---|---|
| Beneficial ownership (Feb 14, 2025) | 9,285 shares; <1% of class |
| Unvested RSUs (as of Dec 29, 2024) | 977 RSUs |
| Stock options | None held by non-employee directors |
| Director stock ownership guideline | 5x annual cash retainer ($450,000) within 5 years of election; all directors in compliance as of Feb 14, 2025 |
| Hedging/derivatives | Prohibited for directors under the Securities Trading Policy |
| Pledging | Officers may not pledge shares; policy specifically restricts pledging by officers; trades by directors require pre-clearance |
Governance Assessment
- Strengths:
- Independent director; audit committee financial expert; chairs Nominating & Corporate Governance—a strong governance profile supporting board effectiveness .
- Solid attendance and engagement; board met 6 times and each director met the ≥75% threshold; all attended the annual meeting .
- Pay structure emphasizes equity (approx. 68% of total), aligning director incentives with shareholders; equity grants are standardized and time-based with clear vesting and change-in-control provisions .
- Robust related party transaction policy overseen by the Nominating & Corporate Governance Committee (chaired by Vounatsos) .
- Investor support signal: 95.7% “say-on-pay” approval in 2024, reflecting general confidence in compensation governance .
- Watch items:
- External board at Zai Lab creates an industry interlock; monitor for any transactions or partnerships involving Revvity and Zai Lab (none disclosed) .
- Securities Trading Policy prohibits hedging for directors; pledging prohibition is explicit for officers—ensure ongoing pre-clearance and adherence by directors .
Overall, Vounatsos brings seasoned pharma/biotech leadership, financial oversight competence, and governance rigor as N&G Chair. Current disclosures show no related-party or attendance red flags, and director compensation/ownership appear aligned with shareholder interests .